Our miniprotein based drug discovery platform uses two proprietary technologies leveraging AI-driven scaffold selection combined with state-of-the-art wet lab screening ensuring exceptional selectivity towards any drug target in a lightning-fast discovery process.
Benefits
Hit validation in 6 months
Radically lower preclinical development costs
AI-powered de novo scaffold selection for any target
Outstanding affinity with extreme selectivity
Applications
use cases
Advancing pharma and biotech with cutting-edge solutions in drug development, cell therapy, and diagnostic innovations.
Drug discovery
Create miniproteins tackling virtually any pharmaceutical target. Achieve high affinity and selectivity matching that of monoclonal antibodies (mAbs).
Cell therapy
Develop novel targeting mechanisms for cell therapy applications. Effectively target T cells through chimeric antigen receptors (CARs) or any other effector cell types (NK, gdT cells, etc.).
Peptide drug conjugate
Use miniproteins as a delivery system for cancer targeting warheads (e.g. toxins). Target cancer antigens including solid tumors thanks to their favorable tissue penetration.
Radioligand therapy
Create new diagnostic and therapy applications. Ideal conjugation partners for delivery of radioligands for diagnostics or therapy (theranostic application) due to high affinity and selectivity, ideal PK profile and high tissue penetration.
Fluorescent dyes
Deliver fluorescent dyes for selective and high affinity labeling of cancer targets for visualization and fluorescent guided surgery applications.
Drug discovery process
WISDOMTM
Wetlab-verified In Silico Design of Miniproteins
01
In silico megalibrary of natural miniprotein scaffolds
The starting point of our solution is naturally occuring peptides with a well-defined structure stabilized by disulfide bonds. We are continuously developing our proprietary virtual miniprotein megalibrary containing a diverse array of stable backbones ensuring drug like properties.
02
Target selection and analysis
Comprehensive structural and functional analyzation of target molecules to identify patches and hotspots to guarantee high affinity binding.
03
AI-driven in silico library filtering
High-performance screening of miniprotein scaffold library towards the target molecule using molecular interaction modeling.
01
In silico megalibrary of natural miniprotein scaffolds
The starting point of our solution is naturally occuring peptides with a well-defined structure stabilized by disulfide bonds. We are continuously developing our proprietary virtual miniprotein megalibrary containing a diverse array of stable backbones ensuring drug like properties.
02
Target selection and analysis
Comprehensive structural and functional analyzation of target molecules to identify patches and hotspots to guarantee high affinity binding.
03
AI-driven in silico library filtering
High-performance screening of miniprotein scaffold library towards the target molecule using molecular interaction modeling.
Drug discovery process
ISEPTM
Individual Sequence Enrichment Pattern
04
Combinatory technology - more than a million variants
The ISEP technology, based on the naturally occurring scaffolds designed by the WISDOM technology, creates a peptide megalibrary with more than a million variants. From the identified peptide analogues, the most promising drug candidates can be selected on the basis of desired pharmacological properties.
05
Individual sequence enrichment pattern
Our “Designer miniprotein” platform can find exceptional drug candidates with unprecedented selectivity and affinity through NGS based enrichment tracking and machine learning based data analysis
06
Characterisation of molecules
In our laboratories, all experimental methods for testing candidate peptide/protein molecules are available. Besides commercially available approaches, we have developed several methods in house to test the newly created peptides for their pharmacological and biological properties such as binding strength, inhibitory or stimulatory effect on target proteins involved in selected diseases.
Chemogenetic Receptor Engineering for Advanced Therapeutics
Cancer, diagnostic tool
01
Combinatory technology - more than a million variants
The ISEP technology, based on the naturally occurring scaffolds designed by the WISDOM technology, creates a peptide megalibrary with more than a million variants. From the identified peptide analogues, the most promising drug candidates can be selected on the basis of desired pharmacological properties.
02
Individual sequence enrichment pattern
Our “Designer miniprotein” platform can find exceptional drug candidates with unprecedented selectivity and affinity through NGS based enrichment tracking and machine learning based data analysis
03
Characterisation of molecules
In our laboratories, all experimental methods for testing candidate peptide/protein molecules are available. Besides commercially available approaches, we have developed several methods in house to test the newly created peptides for their pharmacological and biological properties such as binding strength, inhibitory or stimulatory effect on target proteins involved in selected diseases.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
